Treatment of Androgenetic Alopecia in Transgender People Receiving Testosterone Therapy With Sublingual Minoxidil: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

This study evaluated sublingual minoxidil for treating androgenetic alopecia in transgender individuals on testosterone therapy. In a 24-week randomized, double-blind, placebo-controlled trial with 46 participants, sublingual minoxidil significantly increased hair count in the midfrontal area and showed delayed improvements in the vertex area by Week 48. The treatment was well tolerated, did not affect testosterone levels, and presented no serious adverse events. The study suggests sublingual minoxidil as a viable treatment option for hair growth in this population, though future research should explore long-term efficacy and larger sample sizes.